tyropanoate sodium
Trade name: bilopaque
Small moleculeapproved
Approved
Oct 24, 1969
Tyropanoic acid and its salt sodium tyropanoate are radiocontrast agents used in cholecystography. Trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. This molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones to produce a visible image. After injection it is rapidly excreted into the bile. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1960s
- Oct 24, 1969
General Electric — Earliest FDA Approval
- Oct 24, 1969
General Electric — NDA Secondary Org
- Oct 24, 1969
General Electric — NDA Organization
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedOct 24, 1969
Chemistry & pharmacology
Loading structure…
SMILES
CCCC(=O)Nc1c(I)cc(I)c(CC(CC)C(=O)[O-])c1I.[Na+]- Mol. weight
- 663.01 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTyropanoic acid ↗
- ChEMBLCHEMBL1200899 ↗
Also known as
- bilopaque
- bilopaque
- bilopaque
- sodium tyropanoate
- sodium tyropanoate
- tyropanoate sodium
- tyropanoate sodium
- tyropanoate sodium
- tyropanoate sodium
- tyropanoate sodium
- win-88512
- win-88512
- win-8851-2
- win-8851-2
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | NDA2 | Oct 24, 1969 |
| General Electric | For profit | NDA | Oct 24, 1969 |